However, contradictory results have been observed for the pan HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) as its treatment suppressed OPC survival, leading to detrimental effects for the myelinating brain during stroke recovery [149]. This evidence concerns the gene HDAC9 and Stroke.